STATE OF OKLAHOMA
OKLAHOMA HEALTH CARE AUTHORITY

OHCA 2016-02
January 6, 2016

RE: Non-Invasive Prenatal Testing

Dear Provider,

Beginning January 1, 2016, the Oklahoma Health Care Authority (OHCA) will introduce coverage of non-invasive prenatal testing for fetal autosomal aneuploidy as described by the following molecular pathology CPT codes:

- 81420: Fetal chromosomal aneuploidy genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
- 81507: Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

Prior authorization (PA) will be required for this test. OHCA requires the submission of all of the following documents for PA review:

- HCA-13A Prior Authorization Form Cover Sheet
- HCA-12A Prior Authorization Form
- Objective clinical records supporting the medical necessity of the request

OHCA may consider the use of the test described above to be medically necessary for pregnant women at high risk of aneuploidy. Please note that this new coverage does not extend to non-invasive prenatal testing of sex chromosomal aneuploidy, microdeletions, and/or any other chromosomal anomalies other than aneuploidy of chromosomes 21, 18, and 13.

Thank you for the services you provide to our SoonerCare and Insure Oklahoma members. If you have any questions regarding PA forms and documentation, please contact the OHCA Medical Authorization Unit at 1-800-522-0114.

If you have questions regarding OHCA’s coverage of molecular pathology CPT codes, please contact Alison Martinez, Ph.D. at: alison.martinez@okhca.org.

Sincerely,

Rebecca Pasternik-Ikard
State Medicaid Director